Mater Dei Posts Sharp Profit Decline in Q4 2024, Cancels Treasury Shares

Hospital Mater Dei (MATD3) reported a significant profit decrease in the fourth quarter of 2024. The company’s net profit dropped to R$8.3 million ($1.46 million), representing a 59% decline compared to the same period in 2023.

This performance fell well below market expectations of R$28 million ($4.91 million) according to Bloomberg projections. The healthcare provider’s EBITDA reached R$77.5 million ($13.60 million), marking a 15.2% year-over-year decrease.

Adjusted EBITDA margin contracted to 15.9%, down 4 percentage points from Q4 2023. Revenue also suffered, falling 6% to R$487 million ($85.44 million) compared to the previous year.

Mater Dei attributed the margin decline to three main factors. Revenue growth from units with lower operating margins impacted overall profitability. The Nursing Profession Law increased operational costs across facilities.

Divestment of Hospital Porto Dias reduced the company’s ability to dilute expenses effectively. Operational capacity contracted during the period.

The hospital network operated 1,187 beds on average, representing a reduction of 46 beds year-over-year. Occupancy rates remained relatively stable at 77%. The Q4 performance contrasts sharply with Mater Dei’s stronger results earlier in 2024.

Mater Dei Reports Strong Q3 Growth

The company posted R$75.4 million ($13.23 million) net income in Q3, reflecting a 164% increase from the previous year. First quarter results also showed positive momentum, with revenue up 11% to R$582.8 million ($102.25 million).

Alongside financial results, Mater Dei announced the cancellation of 5,729,500 treasury shares. This strategic move adjusts the company’s capital structure, leaving 339,428,025 common shares outstanding.

The cancellation follows an April 2024 share repurchase program targeting up to 9.6 million shares. Financial forecasts indicate potential recovery ahead.

Analysts project improved margins for 2025-2026, with net margin expected to reach 7.39% in 2025 and 8.77% in 2026. The company maintains an “outperform” consensus rating among nine analysts tracking the stock.

Mater Dei continues focusing on capital structure efficiency despite recent challenges. The average analyst target price of R$6.511 ($1.14) represents a 62.78% premium over the recent closing price of R$4.000 ($0.70).

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.